Lilly Stock Down 5% in a Month: Should You Buy Now or Steer Clear?

Key Takeaways LLY loses about 5% in a month as pricing concerns and rising obesity-drug competition weigh on sentiment.LLY's Mounjaro and Zepbound generated $36.5B in 2025, about 56% of revenues.LLY is advancing an oral obesity pill orforglipron, targeting a U.S. launch in Q2 2026.Shares of Eli Lilly and Company (LLY) have declined 5.2% in the past month despite the company reporting robust fourth-quarter 2025 results on Feb. 4. Industry pricing concerns, rising competitive pressure in the diabetes and obes ...